uniQure
Meibergdreef 61
Amsterdam
1105 BA
Tel: 31-20-566-7394
Fax: 31-20-566-9272
Website: http://www.uniqure.com/
Email: info@uniQure.com
189 articles about uniQure
-
uniQure to Participate in Upcoming Industry Conferences in November
11/1/2021
uniQure N.V. today announced its participation in the following upcoming investor and scientific conferences: The 28th Annual Meeting of the Huntington Study Group (Virtual), November 4 - 6, 2021
-
uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
10/21/2021
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced the appointment of Rachelle Jacques to its Board of Directors.
-
uniQure to Participate in Multiple Upcoming Industry Conferences in October
9/30/2021
uniQure N.V. today announced its participation in the following upcoming investor and scientific conferences: Chardan’s 5th Annual Genetic Medicines Conference, October 4 - 5, 2021
-
uniQure to Participate in Multiple Upcoming Industry Conferences in September 2021
9/7/2021
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced its participation in the following upcoming investor and scientific conferences.
-
The oncogenicity and neurotoxicity risks of AAVs and possible mitigation strategies were the primary focus on Thursday.
-
uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
8/30/2021
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that two additional patient procedures have been completed in the second, higher-dose cohort in the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease.
-
While treatments exist to manage the symptoms of the disease, nothing has proven to be curative – yet. Several biopharma companies are working hard to change that.
-
uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
7/26/2021
uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, reported its financial results for the second quarter of 2021 and highlighted recent progress across its business.
-
Why not take advantage of the perks of a lower cost of living, slower pace, and opportunities to make a big impact in some important disease areas?
-
uniQure has acquired Corlieve with upfront cash of approx. $55 million and will center on the latter's lead program, AMT-260, an advanced treatment for TLE.
-
CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec
5/6/2021
Global biotherapeutics leader CSL Behring announced the closing of its global Commercialization and License agreement with uniQure for etranacogene dezaparvovec, a novel gene therapy for the treatment of hemophilia B. Etranacogene dezaparvovec is currently in Phase 3 clinical trials and has been shown to result in near-normal levels of Factor IX – the blood clotting protein lacking in people with hemophilia B. CSL Behring has been recognized as a global hematology leader for decades.
-
Clinical Catch-Up: April 26-30
5/3/2021
Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications. -
There is hope for uniQure’s HOPE-B trial after all. Shares of uniQure NV are climbing this morning after the company announced the clinical hold on its hemophilia B gene therapy has been lifted by the U.S. Food and Drug Administration.
-
Clinical Catch-Up: March 29-April 2
4/5/2021
It was a busy week for clinical trial news. Here’s a look. -
An investigation was conducted by an independent laboratory and reviewed by leading external experts in the field.
-
The FDA put a clinical hold on UniQure's Phase III trial after a high-risk participant developed liver cancer.
-
In a shining moment that signaled hope for hemophilia B patients, uniQure presented data on Tuesday showing that its gene therapy treatment, etranacogene dezaparvovec (AMT-061), substantially increased production of the blood-clotting protein factor IX in nearly all pivotal Phase III HOPE-B trial...
-
Positive top-line data from UniQure’s Phase III HOPE-B gene therapy trial of etranacogene dezaparvove, an investigational AAV5-based gene therapy, point to a potentially curative treatment for patients with moderate to moderately severe hemophilia B.
-
In June, it dosed its first two patients using a novel therapeutic, AMT-130, delivered directly to the brain. Initial readouts are expected in a year’s time.
-
uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec
10/31/2019
uniQure N.V. announced the publication of 26-week interim data from the ongoing Phase IIb clinical trial of etranacogene dezaparvovec, an investigational gene therapy for hemophilia B, in the journal, Blood Advances.